# Safety and Efficacy of NOM and OPFS Versus RO for dMMR/MSI-H or POLE-Mutated Gastrointestinal Cancers

> **NCT07642323** · — · NOT_YET_RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 22 (estimated)

## Conditions studied

- Gastrointestinal Cancers
- Gastrointestinal Cancers - Stomach
- Gastrointestinal Cancers - Colorectal
- Gastrointestinal Cancers - Anus

## Interventions

- **OTHER:** NOM/OPFS

## Key facts

- **NCT ID:** NCT07642323
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-15
- **Primary completion:** 2027-01-15
- **Final completion:** 2030-01-15
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2026-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07642323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07642323, "Safety and Efficacy of NOM and OPFS Versus RO for dMMR/MSI-H or POLE-Mutated Gastrointestinal Cancers". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07642323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*